학술논문
1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Document Type
Abstract
Author
Source
In Annals of Oncology September 2020 31 Supplement 4:S843-S843
Subject
Language
ISSN
0923-7534